EPISODE · Jul 10, 2026 · 20 MIN
#65. Orbiting around Big Pharma
from Drug Discovery AI Talk · host Dr. Jake Chen
In this episode, we explore Lilly TuneLab as a major signal of where AI drug discovery may be heading: toward powerful platform ecosystems that combine proprietary pharmaceutical data, advanced predictive models, federated learning, and large-scale compute. On the positive side, platforms like TuneLab could help biotech companies derisk drug assets earlier, improve safety and pharmacokinetic predictions, reduce wasted experiments, and give smaller teams access to capabilities once reserved for Big Pharma. At the same time, this new model raises important questions about scientific independence, hidden bias, IP protection, and whether corporate AI platforms could become soft gatekeepers for what counts as a promising drug candidate. The best path forward is not to reject these platforms, but to use them wisely: as acceleration and second-opinion tools, complemented by open benchmarks, independent validation, human-relevant disease models, transparent governance, and mechanism-aware scientific judgment. Produced by Dr. Jake Chen.
What this episode covers
In this episode, we explore Lilly TuneLab as a major signal of where AI drug discovery may be heading: toward powerful platform ecosystems that combine proprietary pharmaceutical data, advanced predictive models, federated learning, and large-scale compute. On the positive side, platforms like TuneLab could help biotech companies derisk drug assets earlier, improve safety and pharmacokinetic predictions, reduce wasted experiments, and give smaller teams access to capabilities once reserved for Big Pharma. At the same time, this new model raises important questions about scientific independence, hidden bias, IP protection, and whether corporate AI platforms could become soft gatekeepers for what counts as a promising drug candidate. The best path forward is not to reject these platforms, but to use them wisely: as acceleration and second-opinion tools, complemented by open benchmarks, independent validation, human-relevant disease models, transparent governance, and mechanism-aware scientific judgment. Produced by Dr. Jake Chen.
NOW PLAYING
#65. Orbiting around Big Pharma
No transcript for this episode yet
Similar Episodes
Mar 31, 2026 ·54m
Mar 27, 2026 ·14m
Mar 24, 2026 ·42m
Mar 20, 2026 ·42m
Mar 17, 2026 ·41m
Mar 13, 2026 ·44m